Clinical trial · Observational
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
Identification and Multicentral Clinical Validation of Plasma Diagnostic Biomarkers for Gastric Cancer Based on Wide-targeted and Targeted Metabolomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction with both broad-spectrum and targeted metabolomics approaches. The goal is to construct a dedicated plasma metabolite database for gastric cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early gastric cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastric cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Gastric cancer group
- description
- Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
- interventionNames
- Other: Gastric cancer
- label
- Non-gastric cancer group
- description
- Patients diagnosed with benign gastric diseases or healthy controls
Primary outcomes (1)
- measure
- Plasma metabolite content
- timeFrame
- Before receiving treatment for gastric cancer
- description
- The outcome will be tested by metabolomics detection technology based on mass spectrometry
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of gastric cancer or benign gastric diseases through gastroscopy and pathological examination. * Collection of plasma samples prior to surgical treatment. * Availability of complete clinical data. Exclusion Criteria: * Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before surgical treatment. * Incomplete clinical data. * Pregnancy status.
References
Publications (0)
Data not yet available